[{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"}]